Tye Cummins lay in the dark, gasping for air and unable to move. He was slipping into a life-threatening, unresponsive state after too much insulin was pumped into his body as he slept. The culprit was an Omnipod insulin pump, a device he wore as part of a clinical trial for patients with type 1 diabetes. “It nearly killed me,” Cummins says. “I was the worst I had ever been. I couldn’t walk or talk for more than two hours.” His experience highlights the dual nature of modern medical technology, both a lifesaver and a potential danger. Over the past decade, diabetes treatment has undergone a transformation. Traditional methods, which relied on finger-prick tests and insulin injections, have been largely replaced by automated insulin pumps and continuous glucose monitors (CGMs). These devices offer real-time glucose data via smartphones, improving blood-sugar control and reducing complications. Dr. Ashley Ng, head of education and professional standards at the Australian Diabetes Educators Association, calls them “life-changing.” However, the widespread adoption of these technologies has also brought a surge in adverse event reports linked to the devices. The Therapeutic Goods Administration (TGA), Australia’s medical devices watchdog, maintains a public database of these reports. Yet, it does not release aggregated data, leaving consumers unaware of which devices are associated with the most incidents. An investigation by this masthead and 60 Minutes used automated web scrapers to extract approximately 81,000 publicly available reports. The findings revealed that diabetes management devices account for seven of the 10 devices with the most adverse-event reports since 2024. They also occupy five of the top 10 spots for injury or death reports. This underscores the growing concern over the balance between technological advancement and regulatory oversight. Many of the complaints center on device accuracy, alarm failures, and connectivity issues. The TGA clarifies that an adverse event report does not necessarily indicate causation and cannot be used alone to assess a device’s safety. Nonetheless, diabetes experts worry that the TGA has relaxed regulatory requirements, enabling the sale of less accurate devices. Meanwhile, U.S. regulators have issued warnings about Bluetooth connections muting blood sugar alarms, a caution that has not been communicated to Australian users. A Victorian coronial inquest is examining five deaths potentially linked to a continuous glucose monitor (CGM) that failed to trigger an alarm due to a Bluetooth issue. The Omnipod 5 insulin pump, widely used in Australia and partially subsidized by the federal government, is associated with 429 adverse-event reports, including 330 injuries, 283 cases of hyperglycaemia, and six instances of diabetic ketoacidosis, a condition requiring intensive care. In the United States, hundreds of deaths have been reported related to insulin pumps. Recently, some batches of the Omnipod 5 were recalled in Australia over an insulin-leaking issue tied to 24 serious events. Device manufacturers attribute the high number of incidents to the large user base. Over 107,000 Australians are approved for monitor subsidies, and more than 146,000 for insulin pumps. The devices come with warnings about Bluetooth interference and instructions for patients to verify readings with finger-prick tests. Despite these precautions, the risks remain. Vicki Kelly’s experience illustrates the broader challenges facing medical device regulation. A 69-year-old Victorian mother of three, she became paralyzed from the waist down after a pump intended to treat her back pain caused a blood clot that blocked a spinal cord artery. “I can’t get up. I can’t walk, I can’t get myself out of bed,” she says. Her case is not unique. According to the Australian Institute of Health and Welfare, over 150,000 medical device-related incidents require hospitalization annually. The TGA, however, refuses to disclose how many reports it receives regarding injuries or deaths linked to devices. To uncover this data, the investigative team employed digital scrapers to extract over 81,000 logs of side effects, recalls, and hazard alerts. Interviews with more than 70 individuals, including patients, doctors, researchers, TGA staff, and industry consultants, revealed a troubling pattern. The number of deaths, injuries, and adverse event reports has steadily increased. Before October 2019, numerous deaths went unlogged until the TGA acknowledged a “technical issue” with its database following inquiries. The TGA’s approval process is also under scrutiny. Only 4.3 percent of the 55,223 devices approved since 2016 underwent detailed conformity assessments. During that period, just 830 devices were rejected. Most medical devices in Australia are approved based on European certification, often granted by for-profit notified bodies in Germany. This approach raises concerns about the independence and rigor of the approval process. As Associate Professor Marco Rizzi explains, the CE mark provides an automatic pathway without independent oversight. Internal TGA documents and staff discussions further expose systemic weaknesses. Employees raised concerns about industry influence, non-compliance, and the regulator’s effectiveness. One noted, “We are biased by serving industry rather than the general public, our most important stakeholder.” Another questioned whether the TGA functions as a regulator or has ignored its responsibilities. These comments reflect deep-seated doubts about the agency’s ability to safeguard public health. The TGA’s reliance on European certification and the ease with which manufacturers can claim substantial equivalence to existing devices means many products bypass rigorous testing. This creates a dangerous precedent, as evidenced by case studies showing the consequences of inadequate oversight. With over 1.4 million medical devices registered in Australia, conducting thorough evaluations for each is impractical. As a former TGA auditor put it, “There are too many devices to deal with.” This has led to a “race to the bottom,” where manufacturers can choose the most lenient certification pathways.
6 reports
The AgeIndependentCenterFactual 60Objective 5513 days agoTye Cummins experienced a life-threatening situation due to an Omnipod insulin pump during a clinical trial for type 1 diabetes. The incident highlights concerns about the safety and reliability of automated insulin pumps and continuous glucose monitors (CGMs). These devices, which have transformed diabetes care by providing real-time glucose data via smartphones, have seen a significant rise in adverse event reports. The Australian Therapeutic Goods Administration (TGA) maintains a public database of these reports but does not publish aggregated data, limiting transparency for consumers. An investigation revealed that diabetes management devices account for seven of the ten most frequently reported devices with adverse events since 2024. Experts express concern over relaxed regulatory standards allowing potentially less accurate devices to be sold. U.S. regulators have issued warnings about Bluetooth connectivity issues affecting blood sugar alarms, which were not communicated to Australian users. A coronial inquest is examining five deaths potentially linked to CGM failure due to Bluetooth interference.
Bias read (Center): The article presents a balanced overview of the risks and benefits of automated diabetes management devices, citing expert opinions and regulatory concerns without overtly favoring either side. While it highlights safety issues and regulatory gaps, it also acknowledges the transformative impact of这些
Why factuality (60): This article closely mirrors item 4, discussing adverse events with CGMs and insulin pumps, and referencing the TGA's role in tracking these issues. It aligns with the broader themes of medical device safety and regulation, even if it doesn't directly address cost-effectiveness.
Why objectivity (55): The tone is critical of the regulatory system but remains objective in its reporting. It presents both the benefits and risks of the technology without overt bias.
The Sydney Morning HeraldIndependentProgressiveFactual 60Objective 5514 days agoAn investigation by The Sydney Morning Herald and 60 Minutes has uncovered significant issues with Australia's medical device regulatory framework. The report highlights that over 150,000 incidents involving medical devices lead to hospitalisations annually, yet the Therapeutic Goods Administration (TGA) does not disclose the number of injury or death reports linked to devices. Using digital scrapers, interviews, and internal documents, the investigation revealed a growing trend in adverse events, including unlogged deaths prior to 2019. The TGA conducts detailed reviews on only 4.3% of approved devices, rejecting just 830 out of 55,223 since 2016. Many devices are approved based on European certifications from for-profit entities, leading to concerns about lax oversight. A TGA insider described the situation as a 'race to the bottom,' where regulators prioritize speed over safety.
Bias read (Progressive): The article critically examines the inadequacies of Australia's medical device regulation, highlighting systemic failures such as lack of transparency, minimal scrutiny of approved devices, and reliance on potentially unreliable international certifications. The tone emphasizes the risks posed to患者,
Why factuality (60): This article touches on CGM and insulin pump usage, mentioning adverse events and the role of the TGA. While it does not directly discuss cost-effectiveness, it aligns with the broader theme of medical device safety and regulation, which is related to the primary source document.
Why objectivity (55): The tone is somewhat critical of the regulatory system but remains focused on factual reporting. It presents both positive and negative aspects of the technology without overt bias.
The Sydney Morning HeraldIndependentCenterFactual 50Objective 6013 days ago It’s changed millions of lives, but this tech ‘nearly killed’ TyeTye Cummins experienced a life-threatening situation due to an Omnipod insulin pump during a clinical trial for type 1 diabetes. The incident highlights concerns about the safety and reliability of automated insulin pumps and continuous glucose monitors (CGMs), which have become increasingly common in diabetes management. These devices, while revolutionary in improving blood-sugar control and reducing complications, have also led to a significant rise in adverse event reports. In Australia, the Therapeutic Goods Administration (TGA) maintains a public database of these reports but does not publish aggregated data, limiting transparency for consumers. An investigation revealed that diabetes management devices account for seven of the top ten devices with the most adverse-event reports since 2024. Experts express concern over the TGA's relaxed regulatory standards, which may allow less accurate devices to enter the market. Meanwhile, U.S. regulators have issued warnings about Bluetooth connectivity issues potentially silencing critical blood sugar alarms, a caution not shared by Australian authorities.
Bias read (Center): The article presents a balanced overview of the risks and benefits of automated insulin pumps and CGMs, citing expert opinions and regulatory concerns without overtly favoring either side. While it highlights potential regulatory shortcomings, it does not take a clear ideological stance on the issue
Why factuality (50): This article continues the discussion of medical device safety and regulatory oversight, referencing Vicki Kelly's case and the broader issue of adverse events. It does not engage with the primary source document about CGM cost-effectiveness. The factual claims are based on reported incidents and da
Why objectivity (60): The article uses vivid storytelling to illustrate the consequences of medical device failures, which may prioritize emotional impact over neutrality. While the factual elements are present, the tone suggests a stronger emphasis on raising awareness about regulatory shortcomings rather than presentin
The AgeIndependentProgressiveFactual 50Objective 4014 days ago ‘Race to the bottom’: Investigation reveals toll of weak medical device lawsThis article discusses the serious risks associated with weak medical device regulations in Australia, highlighting the case of Vicki Kelly, who became paralyzed after complications from a spinal pump. Over 150,000 medical device-related incidents requiring hospitalization occur annually in Australia. The Therapeutic Goods Administration (TGA), Australia's regulatory body, does not disclose injury or death reports linked to devices. An investigative report by The Age and 60 Minutes analyzed over 81,000 government logs and found a rising trend in adverse events, including unlogged deaths prior to 2019. The TGA conducts detailed assessments on only 4.3% of approved devices, with most approvals relying on European certifications rather than local testing. The article notes that devices registered via European notified bodies are significantly more likely to be recalled or issued safety alerts compared to those approved by the U.S. FDA.
Bias read (Progressive): The article frames the issue as a systemic failure of Australia's medical device regulation, emphasizing the lack of oversight and reliance on foreign certification systems. It highlights the potential dangers to patients and criticizes the TGA's lax approach, using terms like 'race to the bottom' (
Why factuality (50): The article discusses medical device safety issues and regulatory failures, but it does not reference the primary source document about CGM cost-effectiveness. Instead, it focuses on a different topic entirely—medical device regulation and safety concerns. As such, it lacks alignment with the primar
Why objectivity (40): The tone is highly critical and emotionally charged, focusing on personal stories and systemic failures. The article presents a strong narrative against the regulatory system without balancing perspectives or providing counterarguments.
The AgeIndependentProgressiveFactual 45Objective 5011 days ago Our medical devices regime is not fit for purposeThe Age editorial criticizes Australia's medical devices regulatory framework, highlighting significant gaps in transparency and safety. Over 1.4 million medical devices are registered with the Therapeutic Goods Administration (TGA), yet the agency refuses to disclose annual injury or death reports linked to these devices. Investigative efforts by The Age and 60 Minutes uncovered more than 80,000 logs of side effects, recalls, and hazard alerts, revealing a rising number of deaths and injuries since 2020—679 deaths and 30,377 injuries. The TGA's website was found to be poorly designed, hindering access to critical data. The investigation also exposed systemic flaws, including reliance on European certifications from for-profit entities in Germany, raising concerns about the independence of the approval process. Experts and TGA insiders have raised alarms about the regulator's effectiveness and potential bias toward industry interests.
Bias read (Progressive): The article frames the shortcomings of the TGA as a systemic failure influenced by industry interests, emphasizing the lack of transparency and accountability. It highlights the reliance on profit-driven European certifications and quotes experts criticizing the regulatory process. While the article
Why factuality (45): The article aligns with the primary source document in discussing medical device regulation and safety issues, though it doesn't directly address CGM cost-effectiveness. It references similar data points about device-related incidents and regulatory shortcomings.
Why objectivity (50): The tone is critical of the regulatory system but maintains a relatively neutral stance. It presents findings without overt emotional bias, though it emphasizes systemic flaws without offering alternative viewpoints.
The Sydney Morning HeraldIndependentProgressiveFactual 45Objective 5011 days ago Our medical devices regime is not fit for purposeAn editorial highlights concerns about the inadequacy of Australia's medical devices regulatory framework, managed by the Therapeutic Goods Administration (TGA). Despite the registration of around 1.4 million medical devices, there are significant challenges in tracking incidents related to these devices. Over 150,000 annual incidents requiring hospital treatment are reported, yet the TGA does not disclose the number of injury or death reports received yearly. Investigative journalism uncovered over 80,000 logs of adverse events, revealing a rise in deaths and injuries since 2020. Issues include a poorly designed TGA website, incomplete data logging, and reliance on European certifications from for-profit entities, raising questions about the independence and effectiveness of the regulatory process.
Bias read (Progressive): The article critiques the current regulatory framework managed by the TGA, highlighting systemic flaws and questioning the independence of the approval process. It emphasizes the potential risks to public health due to inadequate oversight and points to internal doubts within the TGA regarding its效能
Why factuality (45): Similar to item 2, this article discusses medical device regulation and safety issues, referencing the same data about incident rates and regulatory challenges. It does not engage with the primary source document on CGM cost-effectiveness.
Why objectivity (50): The article maintains a critical tone toward the regulatory system but avoids excessive emotional language. It presents facts about device safety and reporting issues without overt bias.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
Australia
